ArticleFrontiers in oncology2026
Low CT-derived vertebral attenuation as a prognostic factor in hepatocellular carcinoma patients treated with immune checkpoint inhibitors.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Computed tomography (CT)-derived vertebral attenuation has been recognized as an indicator of prognosis for patients undergoing tumor removal, liver transplant, or transcatheter arterial chemoembolization (TACE) therapy, but similar research has not been reported in hepatocellular carcinoma (HCC) patients treated with immune checkpoint inhibitors (ICIs). This study aims to explore the prognostic value of CT-derived vertebral attenuation in HCC patients treated with ICIs. Methods: This retrospective study included HCC patients who received ICI treatment at Wuhan Union Hospital between July 2020 and March 2024. CT-derived vertebral attenuation was assessed by measuring mean Hounsfield unit (HU) values in the center of the first lumbar vertebra (L1) on non-contrast CT scans. Based on the optimal cutoff value derived from X-tile software, patients were classified into the CT-derived L1 attenuation-low group (≤100 HU) and the CT-derived L1 attenuation-high group (>100 HU). A comparison of the baseline characteristics of the two groups was made, followed by a propensity score matching (PSM) analysis to balance the variables. The objective response rate (ORR) and disease control rate (DCR) were calculated for both groups, and Kaplan-Meier survival curves and Cox regression models were used to analyze overall survival (OS) and progression-free survival (PFS). Results: The cohort consisted of 357 patients, divided into the L1 attenuation-low group (n = 112) and the L1 attenuation-high group (n = 245). Among all patients, 30.0% (107/357) achieved complete or partial response. After PSM analysis, both groups contained 91 patients. The L1 attenuation-low group had shorter OS (hazard ratio [HR], 1.73; 95% confidence interval [CI], 1.15-2.60; P = 0.008) and PFS (HR, 1.47; 95% CI, 1.04-2.08; P = 0.030) than the L1 attenuation-high group. Conclusion: CT-derived L1 attenuation can stratify survival risk for HCC patients undergoing ICI treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.